Correct Answer: D. All the above
AICD implantation is indicated across multiple arrhythmia syndromes and structural cardiac disease states, making "All of the above" the correct answer. Brugada syndrome (option A) is a primary electrical disease with high sudden cardiac death risk; AICD is the definitive therapy for symptomatic patients or those with high-risk features (fever-triggered arrhythmias, family history of SCD). Ventricular fibrillation (option B) is the most life-threatening arrhythmia; secondary prevention AICD is standard after survived VF arrest. Acute coronary syndrome with reduced ejection fraction (option C) represents post-MI cardiomyopathy; AICD is indicated for primary prevention when LVEF ≤35% persists ≥40 days post-MI (per ACC/AHA and Indian cardiology guidelines). The 2015 ACC/AHA guidelines and Indian Society of Cardiology recommendations recognize AICD as the gold standard for both primary prevention (structural disease, low EF) and secondary prevention (survived life-threatening arrhythmias). Each option independently meets AICD criteria; therefore, all three conditions warrant device implantation, making D the comprehensive and correct answer. This question tests understanding that AICD indications span both primary electrical disorders (Brugada) and secondary prevention (VF) and primary prevention in structural disease (post-MI cardiomyopathy).
Why the other options are wrong
A. Brugada syndrome — While Brugada syndrome is indeed an AICD indication (especially in symptomatic or high-risk patients), selecting only this option ignores that VF and post-MI cardiomyopathy are equally valid indications. This is a partial answer trap—Brugada is correct but incomplete. The question asks for conditions warranting AICD, and all three listed meet criteria. B. Ventricular fibrillation — VF is the classic secondary prevention indication for AICD (post-arrest survivors), but choosing only this option misses primary prevention indications in Brugada syndrome and structural cardiomyopathy. This trap exploits students who anchor on the most dramatic arrhythmia without recognizing that AICD has broader indications across multiple pathologies. C. Acute coronary syndrome with low ejection fraction — Post-MI cardiomyopathy with LVEF ≤35% is a major primary prevention indication, but selecting only this option excludes Brugada (primary electrical disease) and VF (secondary prevention). This trap targets students who focus on structural disease and miss that AICD also covers inherited arrhythmia syndromes and post-arrest scenarios.
High-Yield Facts
- Brugada syndrome AICD indication: Symptomatic patients or those with fever-triggered arrhythmias, family history of SCD, or spontaneous Type 1 ECG pattern warrant AICD (primary electrical disease).
- VF secondary prevention: All survivors of ventricular fibrillation arrest receive AICD regardless of underlying cause (100% indication).
- Post-MI AICD criteria: LVEF ≤35% persisting ≥40 days after MI qualifies for primary prevention AICD per ACC/AHA and Indian cardiology guidelines.
- AICD dual role: Serves both primary prevention (prevent first life-threatening event in high-risk patients) and secondary prevention (prevent recurrence after survived arrhythmia).
- Indian guideline alignment: Indian Society of Cardiology endorses AICD for all three scenarios—inherited channelopathies, post-arrest survivors, and structural cardiomyopathy with reduced EF.
Mnemonics
AICD Indications: PES** Primary electrical (Brugada, LQTS, Catecholaminergic VT) | Events survived (VF, sustained VT arrest) | Structural disease (post-MI EF ≤35%, dilated cardiomyopathy). All three warrant AICD. Post-MI AICD Timing: 40-40 Rule LVEF ≤35% must persist ≥40 days** post-MI before AICD implantation (allows time for myocardial recovery). This prevents unnecessary device implantation in patients with reversible dysfunction.
NBE Trap
NBE exploits the partial answer trap by listing three individually correct AICD indications as separate options, betting students will anchor on one familiar scenario (e.g., VF as the "classic" indication) and miss that the question demands recognition of AICD's broad applicability across primary electrical disease, secondary prevention, and structural cardiomyopathy.
Clinical Pearl
In Indian practice, a 55-year-old post-MI patient with LVEF 30% and a 28-year-old with Brugada syndrome presenting with syncope both receive AICD—the device bridges primary prevention (structural disease) and inherited arrhythmia risk, making it the unifying therapy across seemingly disparate cardiac conditions.
_Reference: Harrison Ch. 226 (Arrhythmias); ACC/AHA 2015 Guidelines for AICD Implantation; Indian Society of Cardiology Consensus Statement on Device Therapy_